Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ... ...

Core Insights - Novo Nordisk has reduced the cash price of its drugs Wegovy and Ozempic to $349 per month, down from $499, aiming to enhance access to its products [1][2] - The price reduction comes in the context of a deal with the Trump administration to lower drug costs on the new direct-to-consumer website, TrumpRx [2] - Novo's drugs generated $7.89 billion in sales in the third quarter, indicating their profitability and market demand [3] Pricing Strategy - Novo Nordisk's competitive pricing includes an introductory offer of $199 per month for the first two months, followed by $349 thereafter [4] - This pricing strategy may exert pressure on competitors like Hims & Hers Health, which is known for its compounded semaglutide offerings [4][5] Market Impact - The reduced pricing is expected to positively impact companies like CVS Health and GoodRx, as these platforms will provide access to the new self-pay options [3] - Hims & Hers Health's stock fell by 3.1% following the announcement, reflecting market reactions to increased competition [5]

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down. ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody technology. https://t.co/AsPJpFZ2pp (Photo: Getty Images) https://t.co/9tdgfIBfXX ...

ToplineNovo Nordisk on Monday lowered the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment Ozempic in a challenge to Eli Lilly’s Zepbound after President Donald Trump announced a deal with the pharmaceutical firms to reduce the U.S. price tag of the popular drugs. Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.Copyright 2023 The Associated Press. All rights reserved.Key FactsThe out-of-pocket monthly pric ...

It's game on! Healthcare stocks ( XLV ) are having a laudable revival, as the market rotation has also benefited the previous stragglers. We also saw pharma stocks (JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha we ...

Core Points - Novo Nordisk has reduced the direct-to-consumer prices of its weight loss drug Wegovy and diabetes drug Ozempic, making them more accessible to patients [1][3] - The new price for existing cash-paying patients is set at $349 per month, down from $499, while the highest dose of Ozempic remains at $499 [1] - A temporary introductory offer allows new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months [2] Pricing Strategy - The introductory offer will end on March 31, after which patients will transition to the new standard monthly price [2] - The Trump administration has facilitated agreements with Novo Nordisk and Eli Lilly to lower drug prices and introduce Medicare coverage for obesity drugs [3][4] - Starting doses of Wegovy and Eli Lilly's Zepbound will be priced at $350 per month on the new TrumpRx platform, with a planned decrease to $245 over two years [4] Partnerships and Accessibility - Novo Nordisk aims to expand access through partnerships with telehealth providers and major retailers, as well as by working with the administration to lower costs for chronic disease patients [4] - The new cash-pay offers are available through Wegovy.com, Ozempic.com, and various participating organizations and telehealth providers [6] - Eli Lilly has also announced a price reduction of $50 on its direct-to-consumer platform, LillyDirect, for its weight loss drug Zepbound [5]

2025 年 11 月 17 日 证券研究报告 行业周报 行业评级： weiyuqi@gwgsc.com 执业证书编号：S0200525060001 联系电话：010-68099389 公司地址：北京市丰台区凤凰嘴街 2 号院 1 号楼中国长城资产大厦 16 层 医药生物行业双周报 2025 年第 23 期总第 146 期 | 报告期：2025.11.3-2025.11.16 | | | --- | --- | | 投资评级 | 看好 | | 评级变动 | 维持评级 | 分析师： huchenxi@gwgsc.com 执业证书编号：S0200518090001 联系电话：010-68085205 创新为源，临床为鉴，效率为盾 聚焦三大投资方向 行业回顾 本报告期医药生物行业指数涨幅为 0.81%，在申万 31 个一级行业中 位居第 21，跑赢沪深 300 指数（-0.27%）。从子行业来看，医药流 通、体外诊断涨幅居前，涨幅分别为 7.61%、5.32%；医疗研发外包、 医疗设备跌幅居前，跌幅分别为 3.49%、1.76%。 行业走势： 估值方面，截至 2025 年 11 月 14 日，医药生物行业 PE（T ...

在前五大重仓股中，微软(MSFT.US)位列第一，持仓约655.14万股，持仓市值约为33.93亿美元，占投资 组合比例为10.49%，持仓数量无变化。 Sea(SE.US)位列第二，持仓约1604.13万股，持仓市值约为28.67亿美元，占投资组合比例为8.86%，持仓 数量无变化。 谷歌(GOOGL.US)位列第三，持仓约1063.14万股，持仓市值约为25.84亿美元，占投资组合比例为 7.99%，持仓数量无变化。 亚马逊(AMZN.US)位列第四，持仓约1104.34万股，持仓市值约为24.25亿美元，占投资组合比例为 7.49%，持仓数量较上季度增加3.35%。 英伟达(NVDA.US)位列第五，持仓约1170.98万股，持仓市值约为21.85亿美元，占投资组合比例为 6.75%，持仓数量无变化。 值得一提的是，Meta从第二季度持仓的头号重仓股跌至第六。老虎环球在第三季度减持Meta 471万股， 大砍持仓62.58%。 | Stock | History | | Shares Held | Market Value | 96 of | Previous % of | Rank | Change ...

Core Insights - The healthcare sector has significantly outperformed the broader market, with the S&P 500 Healthcare Sector index rising over 6% since mid-October, compared to a mere 0.05% increase in the S&P 500 index [1] Group 1: Performance Drivers - Major pharmaceutical companies like Novo Nordisk and Eli Lilly have positively impacted the sector by securing a deal with the Trump administration, allowing them to avoid tariffs for three years and gain access to Medicare and Medicaid patients for their GLP-1 drugs [3] - Eli Lilly's third-quarter results exceeded Wall Street expectations, leading to a 27% increase in its share price over the past month, significantly influencing the sector's performance due to its large market cap [4] - Pfizer also entered a similar agreement with the White House, resulting in a 4% increase in its stock price over the past month [5] - AbbVie reported strong quarterly results, with a 6% increase in its stock price, and projected significant future revenues for its drugs [6] - Amgen's stock surged nearly 15% after reporting better-than-expected revenue and earnings, with its cholesterol drug showing promising results [7] Group 2: Market Sentiment - There is a noticeable flight to safety among investors, as concerns about market overvaluation grow, leading to increased interest in defensive stocks like healthcare [8] - The healthcare sector, along with consumer staples and energy, has outperformed technology and consumer discretionary sectors, indicating a shift in investor sentiment [9]